natgillin/translations-raw huggingface dataset:
One ml of the constituted suspension contains 40 mg voriconazole. (See section 3 ‘How to take VFEND’).
Jedan ml pripremljene suspenzije sadrži 40 mg vorikonazola. (Vidjeti dio 3 "Kako uzimati VFEND").
One ml of the solution contains 0.04 mg zoledronic acid (as monohydrate).
Jedan ml otopine sadrži 0,04 mg zoledronatne kiseline (u obliku hidrata).
One mL pre-filled syringe (Type 1 glass) in a ClickJect pre-filled pen.
Napunjena štrcaljka volumena jedan ml (staklo tipa 1) u napunjenoj brizgalici ClickJect.
One mL pre-filled syringe (Type 1 glass) with flange extenders or one mL pre-filled syringe with a passive needle safety guard and flange extenders.
Napunjena štrcaljka volumena jedan ml (staklo tipa 1) s proširenim rubnikom ili napunjena štrcaljka volumena jedan ml s pasivnim sigurnosnim štitnikom za iglu i proširenim rubnikom.
One ml preservative-free solution in a single–use vial (cyclic olefin polymer plastic resin) with stopper (chlorobutyl elastomer) and seal (aluminium) with flip-off cap (polypropylene).
Jedan ml otopine bez konzervansa u bočici za jednokratnu primjenu (plastična smola od cikličkog olefinskog polimera) s čepom (klorobutilni elastomer) i zatvaračem (aluminij) s „flip-off“ poklopcem (polipropilen).
One ml provides 50 mg of daptomycin after reconstitution with 10 ml of sodium chloride 9 mg/ml (0.9%) solution.
Nakon rekonstitucije s 10 ml otopine natrijevog klorida 9 mg/ml (0,9%), jedan ml sadrži 50 mg daptomicina.
One ml provides 50 mg of daptomycin after reconstitution with 7 ml of sodium chloride 9 mg/ml (0.9%) solution.
Nakon rekonstitucije sa 7 ml otopine natrijevog klorida 9 mg/ml (0,9%), jedan ml sadrži 50 mg daptomicina.
One ml solution contains 0.04 mg zoledronic acid (as monohydrate).
Jedan ml otopine sadržava 0,04 mg zoledronatne kiseline (u obliku hidrata).
One ml solution contains 100 micrograms ziconotide (as acetate).
Jedan ml otopine sadrži 100 mikrograma zikonotida (u obliku zikonotidacetata).
One ml solution contains 100 μg ziconotide (as acetate).
Jedan ml otopine sadrži 100 μg zikonotida (u obliku zikonotidacetata).
One ml solution contains 200 units (equivalent to 6.9 mg) insulin lispro*.
Jedan ml otopine sadrži 200 jedinica (što odgovara 6,9 mg) inzulina lispro*.
One ml solution contains 200 units of insulin lispro (equivalent to 6.9 mg)
Jedan ml otopine sadrži 200 jedinica inzulina lispro (što odgovara 6,9 mg)
One ml solution contains 25 micrograms ziconotide (as acetate).
Jedan ml otopine sadrži 25 mikrograma zikonotida (u obliku zikonotidacetata).
One ml solution contains 25 μg ziconotide (as acetate).
Jedan ml otopine sadrži 25 μg zikonotida (u obliku zikonotidacetata).
One ml solution in a single use pre-filled pen containing a syringe made from type I glass with stainless steel 27 gauge needle.
Jedan ml otopine u napunjenoj brizgalici za jednokratnu primjenu, s ugrađenom štrcaljkom načinjenom od stakla tipa I, s iglom od nehrđajućeg čelika promjera 27 G.
One ml solution in a single use pre-filled syringe made from type I glass with stainless steel 27 gauge needle, with or without needle guard.
Jedan ml otopine u napunjenoj štrcaljki za jednokratnu uporabu od stakla tipa I s iglom promjera 27 G od nehrđajućeg čelika, sa ili bez štitnika za iglu.
One ml solution in a single use pre-filled syringe made from type I glass with stainless steel 27 gauge needle.
Jedan ml otopine u napunjenoj štrcaljki za jednokratnu primjenu, načinjenoj od stakla tipa 1, s iglom od nehrđajućeg čelika promjera 27 G.
One month after co-administration with a 10-valent pneumococcal conjugate vaccine, lower Geometric Mean antibody Concentrations (GMCs) and opsonophagocytic assay (OPA) antibody GMTs were observed for one pneumococcal serotype (18C conjugated to tetanus toxoid carrier protein).
Mjesec dana nakon istovremene primjene s 10-valentnim konjugiranim pneumokoknim cjepivom zamijećene su niže geometrijske srednje vrijednosti koncentracija (GMC – Geometric Mean Antibody Concentration) i niže GMT protutijela na opsonofagocitnom testu (OPA – opsonophagocytic assay) za jedan pneumokokni serotip (18C konjugiran na tetanusni toksoid proteinski nosač).
One month after primary vaccination (i.e. after the third dose), for each vaccine serotype at least 92.7% of subjects achieved ELISA antibody concentrations ≥ 0.2 µg/ml and at least 81.7% achieved OPA titres ≥ 8 except serotype 1 (at least 58.8% with OPA titres ≥ 8).
Jedan mjesec nakon primarnog cijepljenja (tj. nakon treće doze), za svaki serotip sadržan u cjepivu najmanje 92,7% djece je postiglo ELISA koncentraciju protutijela ≥ 0,2 µg/ml, a najmanje 81,7% je postiglo OPA titre ≥ 8, osim za serotip 1 (najmanje 58,8% s OPA titrom ≥ 8).
One month after the booster dose increases of ELISA antibody GMCs and OPA GMTs were seen for each vaccine serotype and the cross-reactive serotype 19A, indicative of immunological memory.
Jedan mjesec nakon dodatne doze zamijećen je porast ELISA GMC-i protutijela i OPA GMT-i za svaki serotip sadržan u cjepivu i ukriženo reaktivni serotip 19A, što ukazuje na imunološku memoriju.
One month after the booster vaccination, the GMTs elicited were significantly higher than those elicited by age matched naïve control groups, indicating that Nimenrix induces immune memory to groups A, C, W-135, and Y.
Mjesec dana nakon docjepljivanja, izazvani GMT-ovi bili su značajno viši od onih izazvanih u kontrolnim skupinama s ispitanicima iste dobi koji nisu prije bili cijepljeni, ukazujući da Nimenrix inducira imunološko pamćenje u grupama A, C, W-135 i Y.
One month after the challenge dose, the GMTs elicited by the subjects primed with Nimenrix increased by 6.5 to 8 fold for groups A, C, W-135 and Y and indicate that Nimenrix induces immune memory to groups A, W-135, and Y. The post-challenge rSBA-group C GMT was similar in both study groups, indicating that Nimenrix induces an analogous immune memory to group C as the licensed MenC-CRM vaccine (Table 7).
Mjesec dana nakon probne doze, postignuti GMTi ispitanika imuniziranih cjepivom Nimenrix povećali su se 6,5 do 8 puta za grupe A, C, W-135 i Y, što ukazuje da Nimenrix inducira imunološko pamćenje na grupe A, W-135 i Y. rSBA-MenC GMT je nakon probne doze bio sličan u obje ispitivane skupine, ukazujući na to da Nimenrix inducira analogno imunološko sjećanje na grupu C kao i ono potaknuto odobrenim cjepivom MenC-CRM (Tablica 7).
One multi-use vial of 4 ml.
Jedna bočica za višestruku primjenu od 4 ml.
One multicentre, double-masked, placebo-controlled, randomised study (BPD OCR 003 PM [VIP- PM]) was conducted in patients with subfoveal choroidal neovascularisation caused by pathological myopia.
Jedno je multicentrično, dvostruko slijepo, placebom kontrolirano, randomizirano kliničko ispitivanje (BPD OCR 003 PM [VIP-PM]) provedeno u bolesnika sa subfovealnom neovaskularizacijom žilnice izazvanom patološkom kratkovidnošću.
One multidose vial of 10 mL capacity contains 1 to 10 mL of solution, corresponding to 1900 to 19000 MBq at date and time of calibration.
Jedna višedozna bočica od 10 ml sadrži 1 do 10 ml otopine, što odgovara 1900 do 19000 MBq na dan i sat kalibriranja.
One multidose vial of 10 mL capacity contains 1 to 10 mL of solution, corresponding to 800 to 8000 MBq at date and time of calibration.
Jedna višedozna bočica od 10 ml sadrži 1 do 10 ml otopine, što odgovara 800 do 8000 MBq na dan i sat kalibriranja.
One multidose vial of 10-mL capacity contains 1 to 10 mL of solution, corresponding to 400 to 4000 MBq at reference date and time.
Jedna multidozna bočica kapaciteta 10 ml sadrži 1 do 10 ml otopine, što odgovara 400 do 4000 MBq u referentnom datumu i vremenu.
One multidose vial of 15 mL capacity containing 1 to 15 mL of solution, corresponding to 1900 to
Jedna višedozna bočica od 15 ml koja sadrži 1 do 15 ml otopine, što odgovara 1900 do 28500 MBq na dan i sat kalibriranja.
One multidose vial of 15 mL capacity containing 1 to 15 mL of solution, corresponding to 800 to 12000 MBq at date and time of calibration.
Jedna višedozna bočica od 15 ml koja sadrži 1 do 15 ml otopine, što odgovara 800 do 12000 MBq na dan i sat kalibriranja.
One multidose vial of 15 mL capacity contains 1 to 15 mL of solution, corresponding to 1900 to 28500 MBq at date and time of calibration.
Jedna višedozna bočica od 15 ml sadrži 1 do 15 ml otopine, što odgovara 1900 do 28500 MBq na dan i sat kalibriranja.
One multidose vial of 15 mL capacity contains 1 to 15 mL of solution, corresponding to 800 to 12000 MBq at date and time of calibration.
Jedna višedozna bočica od 15 ml sadrži 1 do 15 ml otopine, što odgovara 800 do 12000 MBq na dan i sat kalibriranja.
One multidose vial of 15-mL capacity contains 1 to 15 mL of solution, corresponding to 400 to 6000 MBq at reference date and time.
Jedna multidozna bočica kapaciteta 15 ml sadrži 1 do 15 ml otopine, što odgovara 400 do 6000 MBq u referentnom datumu i vremenu.
One MYCLIC pre-filled pen and one alcohol swab (take these from the carton of pens you keep in your refrigerator).
Jednu napunjenu brizgalicu MYCLIC i jedan jastučić natopljen alkoholom (izvadite ih iz kutije s brizgalicama koju držite u hladnjaku).
One needle (5)
Jednu iglu (5)
One needle and one alcohol swab to be used with the pen for administration.
Jedne igle i jedne vate natopljene alkoholom treba se upotrijebiti s brizgalicom za primjenu lijeka.
One non-fatal post marketing case of anaphylactic shock has been reported with aclidinium bromide/formoterol fumarate dihydrate during the current reporting interval.
Tijekom trenutnog izvještajnog intervala, nakon stavljanja lijeka u promet, jedan ne-fatalni slučaj anafilaktičkog šoka zabilježen je kod uporabe aklidinijevog bromida/formoterolfumarat dihidrata.
One of the active substances in Omidria can react with several types of anaesthetics.
Jedna od djelatnih tvari lijeka Omidria može stupiti u interkaciju s nekoliko vrsta anestetika.
One of the active substances in Orkambi, lumacaftor, increases the number of CFTR proteins on the cell surface and the other, ivacaftor, increases the activity of the defective CFTR protein.
Jedna od djelatnih tvari lijeka Orkambi, lumakaftor, povećava količinu CTFR bjelančevina na površini stanica, dok druga, ivakaftor, povećava djelovanje nepravilne CTFR bjelančevine.
One of the active substances in Trifexis, spinosad interferes with certain specific receptors (nicotinic acetylcholine receptors) in the fleas’ nervous system, which results in their subsequent paralysis and death.
Jedna od djelatnih tvari u VMP-u Trifexis, spinosad, interferira s određenim specifičnim receptorima (receptori nikotin acetilkolina) u živčanom sustavu buha, što rezultira njihovom naknadnom paralizom i smrću.
One of the active substances in Xultophy, insulin degludec, is a replacement insulin that acts in the same way as naturally produced insulin and helps glucose enter cells from the blood.
Jedna od djelatnih tvari lijeka Xultophy, degludek inzulin, zamjena je za inzulin koja djeluje na isti način kao i prirodno proizveden inzulin i pomaže glukozi da uđe u stanice iz krvi.
One of the blister units should be separated from the blister card by tearing it apart at the perforations.
Jednu jedinicu blistera treba odvojiti od kartice blistera tako da se otkine po perforaciji.
One of the events occurred on the first day of dabrafenib dosing and recurred following re-challenge at a reduced dose.
Jedan od događaja zabilježen je prvog dana doziranja dabrafeniba i ponovio se nakon ponovnog uvođenja smanjene doze.
One of the excipients in Rivastigmine HEXAL oral solution is sodium benzoate.
Jedna od pomoćnih tvari oralne otopine Rivastigmin HEXAL je natrijev benzoat.
One of the following methods of application of Raplixa may be used based on the type of surgery, location and size and severity of the bleeding:
Ovisno o tipu kirurškog zahvata, veličini i mjestu te jačini krvarenja, može se koristiti jedan od sljedećih načina primjene lijeka Raplixa:
One of the Grade 3 pneumonitis worsened over 11 days with a fatal outcome.
Jedan slučaj pneumonitisa 3. stupnja pogoršavao se tijekom 11 dana i završio smrtnim ishodom.
One of the inactive ingredients in Exelon oral solution is sodium benzoate.
Jedna od pomoćnih tvari u Exelon oralnoj otopini je i natrijev benzoat.
One of the inactive ingredients in Prometax oral solution is sodium benzoate.
Jedna od pomoćnih tvari u Prometax oralnoj otopini je i natrijev benzoat.
One of the inactive ingredients in Rivastigmine HEXAL oral solution is sodium benzoate.
Jedan od neaktivnih sastojaka oralne otopine Rivastigmin HEXAL je natrijev benzoat.
One of the placebo studies also looked at these symptoms in relation to pollen counts.
Jedno od ispitivanja koje je koristilo i placebo razmotrilo je ove simptome u odnosu na količinu cvjetne peludi.
One of the studies also looked at the effect of Tracleer on healing in 190 patients, by measuring the time taken for one selected digital ulcer in each patient to heal completely.
Jedno od ispitivanja također je istražilo djelovanje lijeka Tracleer na liječenje 190 bolesnika, mjereći vrijeme koje je potrebno da se pojedina odabrana digitalna ulceracija u svakog bolesnika potpuno zaliječi.
One of the studies also looked at the effects of Duavive on osteoporosis; however, as there was no benefit of Duavive over the individual components the company withdrew its application for Duavive in the treatment of osteoporosis.
Jedno od ispitivanja također je istražilo djelovanje lijeka Duavive na osteoporozu.
One of the studies involved women weighing 60 kg or less who received a 100-microgram dose of Elonva, and a second study involved women weighing above 60 kg who received a 150-microgram dose.
Jedno od ispitivanja obuhvatilo je žene s tjelesnom težinom od 60 kg ili manje koje su primile dozu od 100 mikrograma lijeka Elonva, dok je drugo ispitivanje obuhvatilo žene tjelesne težine veće od 60 kg koje su primile dozu od 150 mikrograma.
One of the studies was in patients aged over 12 years, while the other involved patients aged between six and 12 years.
Jedno od ispitivanja provedeno je u bolesnika starijih od 12 godina, dok je drugo ispitivanje obuhvatilo bolesnike u dobi između šest i 12 godina.
One of the studies, which involved 1,196 patients, also showed that the combination of RoActemra and methotrexate slowed down the damage to the joints and improved physical function after up to 2 years, when compared with the combination of placebo and methotrexate.
U jednom od ispitivanja, kojim je bilo obuhvaćeno 1 196 bolesnika, također se pokazalo da je kombinacija lijeka RoActemra i metotreksata nakon razdoblja do dvije godine usporila oštećenje zglobova i poboljšala fizičke funkcije, u usporedbi s kombinacijom placeba i metotreksata.
One of the three trials also included a comparison with latanoprost (another prostaglandin analogue used for glaucoma). .
Jedno od tri ispitivanja uključilo je također usporedbu s latanoprostom (drugim analogom prostaglandina koji se koristi za liječenje glaukoma).
One of these metabolites inhibits the proliferation of VEGF-stimulated human umbilical vein endothelial cells with a similar potency to that of pazopanib, the others are 10- to 20- fold less active.
Jedan od tih metabolita inhibira proliferaciju endotelijalnih stanica umbilikalne vene stimuliranih VEGF-om potentnošću sličnom pazopanibu, dok su ostali 10- do 20-puta manje aktivni.
One of these prevention studies compared Pradaxa with warfarin and the other compared Pradaxa with placebo (a dummy treatment).
U jednom od tih ispitivanja prevencije lijek Pradaxa uspoređen je s varfarinom, dok je u drugom ispitivanju lijek Pradaxa uspoređen s placebom (prividnim liječenjem).
One of these studies also compared Urorec with tamsulosin (another medicine used for BPH).
U jednom od ovih ispitivanja Urorec je također uspoređen s tamsulozinom (drugim lijekom za liječenje BHP-a).
One of these studies examined Enbrel’s effects as an add-on to methotrexate in 89 patients.
Jedno od ovih ispitivanja istražilo je djelovanje lijeka Enbrel kao dodatka metotreksatu u 89 bolesnika.
One of these studies involved patients with ‘HBeAg-negative’ hepatitis B, a type that is more difficult to treat, while the other involved the more common HBeAg- positive’ hepatitis B. A third study involving 112 adults whose liver had stopped working properly (decompensated liver disease) compared Viread with entecavir and a combination treatment of Viread and emtricitabine.
„HBeAg negativnim” hepatitisom B, tipom koji se teže liječi, dok je drugo ispitivanje uključivalo uobičajeniji „HBeAg pozitivan” hepatitis B. Treće je ispitivanje obuhvatilo 112 odraslih osoba čija je jetra prestala ispravno funkcionirati (dekompenzirana bolest jetre) te je usporedilo Viread s entecavirom i kombiniranim liječenjem lijekom Viread i emtricitabinom.
One of these studies showed that Repatha given together with other fat-lowering medicines reduced fat levels in the blood after 12 weeks of treatment (around 15 to 32% more than placebo given on top of other fat lowering medicines).
U jednom od ovih ispitivanja dokazano je da je lijek Repatha, primijenjen s drugim lijekovima za snižavanje koncentracije masti u krvi, smanjio koncentracije masti u krvi nakon 12 tjedana terapije (otprilike 15 do 32 % više u odnosu na placebo koji se primjenjivao uz druge lijekove za smanjivanje koncentracije masti).
One of these treatments may include bone marrow transplantation.
Jedna od tih terapija može uključivati presađivanje koštane srži.
One open label, multicentre, phase II clinical trial (study B2225) was conducted testing Glivec in diverse populations of patients suffering from life-threatening diseases associated with Abl, Kit or PDGFR protein tyrosine kinases.
Provedeno je jedno otvoreno, multicentrično kliničko ispitivanje faze II (studija B2225) za ispitivanje Gliveca u raznim populacijama bolesnika koji pate od bolesti opasnih po život povezanih s Abl, Kit ili PDGFR protein tirozin kinazama.
One open label, multicentre, phase II clinical trial (study B2225) was conducted testing imatinib in diverse populations of patients suffering from life-threatening diseases associated with Abl, Kit or PDGFR protein tyrosine kinases.
Provedeno je jedno otvoreno, multicentrično kliničko ispitivanje faze II (studija B2225) za ispitivanje imatiniba u raznim populacijama bolesnika koji boluju od životno ugrožavajućih bolesti povezanih s Abl, Kit ili PDGFR protein tirozin kinazama.
One open label, multicentre, phase II clinical trial (study B2225) was conducted testing imatinib in diverse populations of patients suffering from life-threatening diseases associated with Abl, Kit or PDGFR protein tyrosine kinases.
Provedeno je jedno otvoreno, multicentrično kliničko ispitivanje faze II (studija B2225) za ispitivanje imatiniba u raznim populacijama bolesnika koji pate od bolesti koje ugrožavaju život povezanih s Abl, Kit ili PDGFR protein tirozin kinazama.
One open label, multicentre, phase II clinical trial (study B2225) was conducted testing imatinib in diverse populations of patients suffering from life-threatening diseases associated with Abl, Kit or PDGFR protein tyrosine kinases.
Provedeno je jedno otvoreno, multicentrično kliničko ispitivanje faze II (studija B2225) za ispitivanje imatinibom u raznim populacijama bolesnika koji pate od bolesti opasnih po život povezanih s Abl, Kit ili PDGFR protein tirozin kinazama.
One open-label, multicentre, phase II clinical trial (study B2225) was conducted testing imatinib in diverse populations of patients suffering from life-threatening diseases associated with Abl, Kit or PDGFR protein tyrosine kinases.
Provedeno je jedno otvoreno, multicentrično kliničko ispitivanje faze II (studija B2225) za ispitivanje imatiniba u raznim populacijama bolesnika koji pate od bolesti koje ugrožavaju život povezanih s Abl, Kit ili PDGFR protein tirozin kinazama.
One Oprymea 0.26 mg prolonged-release tablet.
Jedna Oprymea 0,26 mg tableta s produljenim oslobađanjem
One Oprymea 0.52 mg prolonged-release tablet, OR
Jedna Oprymea 0,52 mg tableta s produljenim oslobađanjem ILI
One Oprymea 1.05 mg prolonged-release tablet, OR
Jedna Oprymea 1,05 mg tableta s produljenim oslobađanjem ILI
One or 12 bottles of 10 ml (10 doses), 50 ml (50 doses), 100 ml (100 doses) or 250 ml (250 doses) packed in a cardboard box.
1 ili 12 bočica od 10 ml (10 doza), 50 ml (50 doza), 100 ml (100 doza) ili 250 ml (250 doza) pakiranih u kartonske kutije.
One or 2 separate needles may be available in the secondary packaging of the presentation containing the pre-filled syringe without the attached needle
Jedna ili dvije zasebne igle mogu biti priložene u sekundarnom pakiranju koje sadrži napunjenu štrcaljku bez spojene igle.
One or more areas in which grey matter activity is intense and clearly exceeds activity in adjacent white matter.
Jedno ili više područja u kojem je aktivnost sive tvari intenzivna i jasno nadmašuje aktivnost u susjednoj bijeloj tvari.
one or more of the following problems in the mouth: ulcer, loss of sensation, discomfort, unusual colour, soft tissue disorder, tongue disorder, painful or blistered or ulcerated tongue, gum pain, chapped lips, tooth disorder
jedan ili više od sljedećih teškoća u ustima: ranice, gubitak osjeta, nelagoda, neuobičajena boja, poremećaji mekog tkiva, poremećaji jezika, bolan jezik ili mjehurići ili ranice na jeziku, bol u desnima, ispucale usne, poremećaji zuba
One or two 30 mg Ebilfumin capsule(s)
jedna ili dvije Ebilfumin kapsule od 30 mg
One or two 30 mg Tamiflu capsule(s)
Ako su Vam potrebne manje doze lijeka, p jedna ili dvije Tamiflu kapsule od 30 m
one orange 80 mg + one grey 20 mg
jedna narančasta kapsula od 80 mg + jedna siva kapsula od 20 mg
one orange 80 mg + three grey 20 mg COMETRIQ capsules are also available in 28 day packs:
jedna narančasta kapsula od 80 mg + tri sive kapsule od 20 mg COMETRIQ kapsule također su dostupne u pakiranjima za 28 dana:
One out of 168 patients (0.6%) tested positive for anti-siltuximab antibodies at a single time point using the high medicinal product-tolerant ECLIA assay.
Jedan od 168 bolesnika (0,6%) imao je pozitivan rezulat anti-siltuksimab protutijela u jednom trenutku koristeći ECLIA pretragu koja je visoko tolerantna na lijek.
one pack containing 50 vials of 2.5 ml suspension (antigen) two packs containing 25 vials of 2.5 ml emulsion (adjuvant)
jedno pakiranje s 50 bočica s 2,5 ml suspenzije (antigen) dva pakiranja s 25 bočica s 2,5 ml emulzije (adjuvans)
One pack containing: one pack of 50 vials (type I glass) of 2.5 ml suspension with a stopper (butyl rubber). two packs of 25 vials (type I glass) of 2.5 ml emulsion with a stopper (butyl rubber).
Jedno pakiranje sadrži: jedno pakiranje s 50 bočica (staklo tip I) od 2,5 ml suspenzije s čepom (butil guma). dva pakiranja s 25 bočica (staklo tip I) od 2,5 ml emulzije s čepom (butil guma).
One pack containing: one pack of 50 vials (type I glass) of 2.5 ml suspension with a stopper (butyl rubber). two packs of 25 vials (type I glass) of 2.5 ml emulsion with a stopper (butyl rubber).
Jedno pakiranje sadrži: jedno pakiranje s 50 bočica (staklo tip I) od 2,5 ml suspenzije, s čepom (butil guma). dva pakiranja s 25 bočica (staklo tip I) od 2,5 ml emulzije, s čepom (butil guma).
One pack containing: one pack of 50 vials (type I glass) of 2.5 ml suspension with a stopper (butyl rubber). two packs of 25 vials (type I glass) of 2.5 ml emulsion with a stopper (butyl rubber).
Jedno pakovanje sadrži: jedno pakovanje s 50 bočica (staklo tip I) od 2,5 ml suspenzije s čepom (butil guma). dva pakovanja s 25 bočica (staklo tip I) od 2,5 ml emulzije s čepom (butil guma).
One pack contains 1, 4 or 6 pre-filled syringes.
Jedno pakovanje sadrži 1, 4 ili 6 napunjenih štrcaljki.
One pack contains 1, 5 or 10 of the following: glass vial of OBIZUR 500 U white, friable powder with a rubber stopper and a flip-off seal pre-filled glass syringe of 1 ml sterilised water for injections with a rubber tip cap and a Luer Lock adapter fluid transfer device with an integral plastic spike
Jedno pakiranje sadrži 1, 5 ili 10 sljedećeg: staklena bočica lijeka OBIZUR 500 U u obliku bijelog, rastresitog praška s gumenim zatvaračem i "flip-off" prstenom napunjena staklena štrcaljka od 1 ml sterilizirane vode za injekcije s gumenim zatvaračem vrha i Luer Lock adapterom uređaj za prijenos tekućine s ugrađenim plastičnim šiljkom